dK_FSHRxCD3

dK_FSHRxCD3 is a DNA-encoded bispecific T-cell engager (dKBTE) designed for the treatment of ovarian cancer. Developed using a synthetic DNA (synDNA) platform, it utilizes "knob-into-hole" technology to facilitate the in vivo assembly and secretion of bivalent bispecific antibodies. The molecule targets the Follicle Stimulating Hormone Receptor (FSHR), which is overexpressed in approximately 70% of ovarian tumors with minimal expression in healthy tissues, and the CD3 receptor on T cells to induce targeted cytotoxicity. By delivering the genetic sequence via synDNA rather than the protein itself, the platform aims to overcome the short half-life and complex manufacturing challenges associated with first-generation bispecific T-cell engagers (BTEs). Preclinical studies have demonstrated that dK_FSHRxCD3 induces potent T-cell activation, cytokine secretion, and specific killing of ovarian cancer cell lines, showing superior pharmacokinetics and tumor control in vivo compared to traditional BTE formats.

Other names

FSHR x CD3 dKBTEDNA-encoded FSHR x CD3 bispecific T-cell engager